A contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO), is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.
Services offered by CMOs include, but are not limited to: pre-formulation, formulation development, stability studies, method development, pre-clinical and Phase I clinical trial materials, late-stage clinical trial materials, formal stability, scale-up, registration batches and commercial production. CMOs are contract manufacturers, but they can also be more than that because of the development aspect.

Rentschler Biopharma and Leukocare reported about effective cooperation

Rentschler Biopharma SE, a leading contract development and manufacturing organization, and Leukocare AG, a biotechnology company, reported on the successful first year of their unique strategic alliance.

iBio expanded its CDMO capabilities for manufacturing of Fc Fusion Proteins

IBio announced the expansion of its CDMO capabilities and services to include the development and cGMP manufacturing of Fc fusion proteins for therapeutic pharmaceutical applications.

Richard Král was appointed as a new CEO of Saneca Pharma CDMO

Richard, who has been the sales and marketing director at Saneca for almost three years, has previously worked for GlaxoSmithKline and Zentiva Group.

Cobra Biologics and Symbiosis received a $2.5 million grant

Cobra Biologics, a contract development and manufacturing organisation of biologics, and Symbiosis Pharmaceutical Services, a contract manufacturing organisation, announced that they have been awarded a collaborative grant

South Korean SK Biotek opens a manufacturing campus in Ireland

SK Biotek has confirmed that it plans to operate and develop Swords Campus as a stand-alone CDMO, which will manufacture pharma products to specification for other pharmaceutical companies on a contract basis

CDMO KBI Biopharma strengthens its positions

KBI Biopharma, Inc., a biopharmaceutical Contract Development & Manufacturing Organization, has completed the acquisition of the assets of Elion Labs , a leading contract services organization

German CDMO HERMES PHARMA receives Russian GMP certification

HERMES PHARMA, a German company, focused on developing and manufacturing of solid oral dosage forms, successfully completed the GMP inspection of its production facilities by Russian authorities

STA Pharmaceutical sees rapid growth in MAH programs in China

STA Pharmaceutical reports that it has seen a rapid uptake in companies with intent to market their products in China

CDMO Brammer Bio launches its renovated cGMP manufacturing site

Brammer Bio announced the completion of renovations and launch of its late-stage clinical capacity and commercial-ready cGMP manufacturing site

Eurofins enhances its CDMO capacities

test tubes
Eurofins Scientific recently enhanced its leadership in biopharmaceutical services and expanded its Contract Development and Manufacturing offering

Fujifilm amplifies the capacity of its biopharmaceutical CDMO sites

FUJIFILM is to invest approximately EUR 24 million on its CDMO sites in the USA and the UK

CDMO Celonic buys bio-manufacturing facility in Germany

Celonic AG and Glycotope announced the successful completion of Celonic’s acquisition of Glycotope’s bio-manufacturing facility in Heidelberg, Germany

CDMO Almac acquires BioClin Laboratories

Almac Group, the global contract development and manufacturing organisation, today announced the acquisition of 100% shares of BioClin Laboratories

Novasep pushes up cGMP capacity of its API manufacturing facility

Novasep announced a €4M investment to expand cGMP capacity for clinical and commercial supply of APIs at its Chasse-sur-Rhône facility in France

Servier CDMO invests $7.5 million in its stepped-up technology

The contract development and manufacturing organization, division of Servier, yesterday announced that the company has invested $7.5 million in intensified technology

CDMO Pfizer CentreOne opens new manufacturing facility in Japan

Pfizer CentreOne, a global contract manufacturing organization embedded within Pfizer, announced that it is now offering services in Nagoya, Japan